Catalyst Pharmaceuticals, Inc. (CPRX)
| Market Cap | 3.85B +46.6% |
| Revenue (ttm) | 596.96M +11.7% |
| Net Income | 221.32M +12.1% |
| EPS | 1.73 +10.3% |
| Shares Out | 122.42M |
| PE Ratio | 18.19 |
| Forward PE | 15.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,346,495 |
| Open | 31.47 |
| Previous Close | 31.47 |
| Day's Range | 31.47 - 31.48 |
| 52-Week Range | 19.05 - 32.56 |
| Beta | 0.74 |
| Analysts | Hold |
| Price Target | 31.67 (+0.64%) |
| Earnings Date | Aug 5, 2026 |
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticoste... [Read more]
Financial Performance
In 2025, Catalyst Pharmaceuticals's revenue was $588.99 million, an increase of 19.78% compared to the previous year's $491.73 million. Earnings were $214.33 million, an increase of 30.78%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CPRX stock is "Hold." The 12-month stock price target is $31.67, which is an increase of 0.64% from the latest price.
News
Solaris to replace Catalyst Pharmaceuticals in the S&P 600 at open on 7/15
Solaris Energy Infrastructure (SEI) will replace Catalyst Pharmaceuticals (CPRX) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 15. Angelini Pharma S.p.A. is acqu...
Catalyst Pharmaceuticals Transcript: EGM 2026
Stockholders voted on a merger with Angelini Pharma S.p.A., approving the merger proposal but not the advisory compensation proposal. The adjournment proposal was not needed as the merger passed.
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses Data Demonstrate V...
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on June 30, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Catalyst Pharmaceuticals (CPRX) to Neutral from Buy with a $31.50 price target after the company agreed to be acquired by Angelini Pharma at a price of $31.50…
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on May 12, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 79c, consensus 64c
Reports Q1 revenue $149.4M, consensus $148.18M. FIRDAPSE Q1 2026 product revenue, net was $98.9 million, an 18.1% year-over-year increase, primarily driven by increases in sales volumes. AGAMREE Q1 20...
Catalyst Pharmaceuticals not providing forward-looking guidance
In light of the Company’s May 7, 2026 announcement, Catalyst will not be providing forward-looking guidance or updates to previously issued guidance. In addition, the Company will not host an…
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funde...
Catalyst Pharmaceuticals Quarterly report: Q1 2026
Catalyst Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 11, 2026.
Catalyst Pharmaceuticals Earnings release: Q1 2026
Catalyst Pharmaceuticals released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Catalyst Pharmaceuticals downgraded to Neutral from Buy at Citi
Citi downgraded Catalyst Pharmaceuticals (CPRX) to Neutral from Buy with a $31.50 price target after Angelini Pharma announced it will acquire Catalyst for $4.1B, or $31.50 per share. The firm…
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, deve...
Catalyst Pharmaceuticals downgraded to Neutral from Outperform at Baird
Baird downgraded Catalyst Pharmaceuticals (CPRX) to Neutral from Outperform with an unchanged price target of $32 after Angelini Pharma agreed to acquire Catalyst for $31.50 per share in cash or…
Catalyst Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Leland Gershell downgraded Catalyst Pharmaceuticals (CPRX) to Perform from Outperform without a price target after Angelini Pharma agreed to acquire Catalyst for $31.50 per share i...
Catalyst Pharmaceuticals downgraded to Equal Weight from Overweight at Stephens
Stephens downgraded Catalyst Pharmaceuticals (CPRX) to Equal Weight from Overweight with a $32 price target after the company announced its settlement with Hetero regarding Firdapse patent litigation ...
Catalyst Pharmaceuticals to be acquired by Angelini Pharma for $31.50 per share
Angelini Pharma and Catalyst Pharmaceuticals (CPRX) announced that they have entered into a definitive agreement pursuant to which Angelini Pharma has agreed to acquire all outstanding shares of Catal...
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on May 7, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on May 7, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal
The move marks Italy's Angelini Pharma's entry into the U.S. market.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla.
Italy's Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
Italy's Angelini Pharma said on Thursday it has agreed to acquire Catalyst Pharmaceuticals for $4.1 billion.